Tourmaline Bio, Inc.
TRML
$19.00
$0.120.64%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 22.58M | 22.75M | 24.36M | 22.13M | 17.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 98.45M | 89.73M | 78.82M | 61.02M | 55.42M |
| Operating Income | -98.45M | -89.73M | -78.82M | -61.02M | -55.42M |
| Income Before Tax | -82.87M | -73.21M | -63.88M | -49.29M | -47.93M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -82.87 | -73.21 | -63.88 | -49.29 | -47.93 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -82.87M | -73.21M | -63.88M | -49.29M | -47.93M |
| EBIT | -98.45M | -89.73M | -78.82M | -61.02M | -55.42M |
| EBITDA | -98.41M | -89.69M | -78.78M | -60.98M | -55.39M |
| EPS Basic | -3.22 | -2.88 | -2.82 | -7.20 | -22.81 |
| Normalized Basic EPS | -2.20 | -1.98 | -1.78 | -4.52 | -14.28 |
| EPS Diluted | -3.22 | -2.88 | -2.82 | -7.20 | -22.81 |
| Normalized Diluted EPS | -2.20 | -1.98 | -1.78 | -4.52 | -14.28 |
| Average Basic Shares Outstanding | 102.98M | 101.37M | 91.58M | 66.89M | 42.16M |
| Average Diluted Shares Outstanding | 102.98M | 101.37M | 91.58M | 66.89M | 42.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |